CCTG CO.26: Updated analysis and impact of plasma-detected microsatellite stability (MSS) and tumor mutation burden (TMB) in a phase II trial of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with refractory metastatic colorectal carcinoma (rmCRC).

被引：14
|
作者：
Chen, Eric Xueyu
Jonker, Derek J.
Loree, Jonathan M.
Kennecke, Hagen F.
Berry, Scott R.
Couture, Felix
Ahmad, Chaudhary E.
Goffin, John R.
Kavan, Petr
Harb, Mohammed
Colwell, Bruce
Samimi, Setareh
Samson, Benoit
Abbas, Tahir
Aucoin, Nathalie
Aubin, Francine
Koski, Sheryl L.
Wei, Alice Chia-chi
Tu, Dongsheng
O'Callaghan, Christopher J.
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada
[3] BC Canc, Vancouver, BC, Canada
[4] Virginia Mason Hosp & Med Ctr, Seattle, WA USA
[5] Univ Toronto, Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[6] Ctr Hosp Univ Quebec, Quebec City, PQ, Canada
[7] Newfoundland Canc, St John, NF, Canada
[8] Juravinski Canc Ctr, Burlington, ON, Canada
[9] McGill Univ, Montreal, PQ, Canada
[10] Moncton Hosp, Moncton, NB, Canada
[11] Nova Scotia Canc Ctr, Halifax, NS, Canada
[12] Univ Montreal, Sacre Coeur Hosp, Montreal, PQ, Canada
[13] Hop Charles LeMoyne, Quebec City, PQ, Canada
[14] Univ Saskatchewan, Saskatoon Canc Ctr, Saskatchewan Canc Agcy, Saskatoon, SK, Canada
[15] Hop Cite Sante Laval, Laval, PQ, Canada
[16] CHUM, Montreal, PQ, Canada
[17] Cross Canc Inst, Edmonton, AB, Canada
[18] Univ Toronto, Toronto, ON, Canada
[19] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.3512
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3512
引用
收藏
页数：2
相关论文
共 4 条
  • [1] CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
    Chen, Eric Xueyu
    Jonker, Derek J.
    Kennecke, Hagen F.
    Berry, Scott R.
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl L.
    Wei, Alice Chia-chi
    Magoski, Nadine M.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [2] Tissue and plasma tumor mutation burden (TMB) as predictive biomarkers in the CO.26 trial of durvalumab plus tremelimumab (D plus T) versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).
    Loree, Jonathan M.
    Topham, James T.
    Kennecke, Hagen F.
    Feilotter, Harriet
    Keshavarz-Rahaghi, Faeze
    Lee, Young S.
    Li Weimin
    Quinn, Katie
    Banks, Kimberly
    Renouf, Daniel John
    Jonker, Derek J.
    Tu Dongsheng
    O'Callaghan, Christopher J.
    Chen, Eric Xueyu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [3] Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).
    Loree, Jonathan M.
    Topham, James T.
    Kennecke, Hagen Fritz
    Feilotter, Harriet
    Lee, Young S.
    Virk, Shakeel
    Kopetz, Scott
    Duose, Dzifa Yawa
    Manyam, Ganiraju C.
    Morris, Jeffrey S.
    Maru, Dipen M.
    Renouf, Daniel
    Jonker, Derek J.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    Chen, Eric Xueyu
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [4] The CCTG C0.26 trial: A phase II randomized study of durvalumab plustremelimumab and best supportive care (BSC) vs BSC alone in patients with advanced colorectal carcinoma (CRC) refractory to standard therapies.
    Chen, Eric Xueyu
    Jonker, Derek J.
    Kennecke, Hagen F.
    Koski, Sheryl L.
    Wei, Alice Chia-chi
    Magoski, Nadine M.
    Tu, Dongsheng
    O'Callaghan, Christopheri J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
1